Ignite Creation Date:
2025-12-24 @ 7:13 PM
Ignite Modification Date:
2025-12-28 @ 11:25 PM
Study NCT ID:
NCT05203003
Status:
RECRUITING
Last Update Posted:
2024-12-06
First Post:
2022-01-10
Is Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Prospective Evaluation of the Prognostic Impact of Measurable Residual Disease (MRD) Within a Phase III Study Comparing a Fixed Duration Therapy Versus Continuous Therapy With Daratumumab, Lenalidomide, and Dexamethasone for Relapsed Multiple Myeloma Requiring a First Salvage Treatment.
Sponsor:
Assistance Publique - Hôpitaux de Paris
Organization:
Organization Data
Organization:
Class:
OTHER
Study ID:
APHP210482
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Lead Sponsor Class:
OTHER
Responsible Party:
Responsible Party Title:
Responsible Party Type:
SPONSOR
Responsible Party Affiliation:
Old Name:
None
Old Organization:
None